| Literature DB >> 31791333 |
Ida M Grønborg1,2, Inge Tetens3,4, Elisabeth Wreford Andersen5,6, Michael Kristensen7, Rikke E K Larsen7, Thanh L L Tran7, Rikke Andersen3.
Abstract
BACKGROUND: Deficient and insufficient vitamin D status (defined as serum 25(OH)D < 30 nmol/L and > 50 nmol/L) is prevalent worldwide and associated with decreased muscle strength and poor bone health. We aimed to investigate the effect of vitamin D fortification on bone markers and muscle strength among younger adult women at risk of vitamin D deficiency.Entities:
Keywords: Bone regeneration; Bone resorption; Food; Fortified; Immigrants; Muscle strength; Ranomised controlled trial; Vitamin D
Year: 2019 PMID: 31791333 PMCID: PMC6889210 DOI: 10.1186/s12937-019-0504-9
Source DB: PubMed Journal: Nutr J ISSN: 1475-2891 Impact factor: 3.271
Baseline characteristics of participants by study group and ethnicity1
| Danish | Pakistani | |||||
|---|---|---|---|---|---|---|
| Total ( | Placebo ( | Fortified ( | Total ( | Placebo ( | Fortified ( | |
| Born in Denmark (%) | 99 | 100 | 99 | 62 | 70 | 54 |
| Years lived in Denmark2 | – | – | – | 20 | 21 | 18 |
| Mean age in years (SD) | 33 (11) | 34 (11) | 32 (11) | 36 (9) | 36 (9) | 36 (10) |
| Age range (years) | 18–50 | 18–50 | 18–50 | 18–50 | 18–50 | 18–47 |
| Mean weight in kg (SD) | 68 (13) | 70 (15) | 67 (11) | 70 (12) | 68 (13) | 70 (12) |
| BMI (kg/m2)* | 24 (5) | 25 (5) | 24 (4) | 27 (5) | 27 (5) | 27 (5) |
| Mean serum 25(OH)D (nmol/L) | 49.6 (18) | 46.2 (19) | 53.3 (17) | 46.9 (22) | 49.0 (23) | 44.5 (21) |
| Mean plasma creatinine (μmol/l) | 61.4 (10) | 61.4 (9) | 61.4 (10) | 58.0 (9) | 57.8 (10) | 58.0 (8) |
| Median dietary vitamin D intake (μg/d)* | 1.5 (1.0; 2.0) | 1.5 (1.0; 2.0) | 1.7 (1.0; 2.1) | 1.1 (1.0; 2.0) | 1.1 (0.8; 1.4) | 1.0 (0.7; 1.7) |
| Median dietary calcium intake (mg/d) | 465 (324; 688) | 487 (309; 685) | 442 (331; 692) | 441 (260; 589) | 422 (262; 547) | 465 (259; 634) |
| Smokers (%) | 14 | 14 | 13 | 4 | 3 | 6 |
| Alcohol drinkers (%)¶ | 86 | 89 | 84 | 1.4 | 3 | 0 |
| Wearing hijab (%)¶ | 0 | 0 | 0 | 44 | 43 | 45 |
1Means and SD unless otherwise specified. If non-normally distributed, medians and 25th and 75th percentiles.
2Years lived in Denmark on average, if not born in Denmark.
*Significant difference between Danish (all) and Pakistani (all) women in an unpaired t test (P < 0.05).
¶Significant difference between Danish (all) and Pakistani (all) women in a Pearson’s chi2 test.
Baseline self-reported physical activity and self-rated health
| Danish | Pakistani | |
|---|---|---|
| Physical activity score, no job1, n (%) | n total DK = 3 | n total Pa = 22 |
| 1: Sedentary | 0 (0%) | 3 (14%) |
| 2: Light | 1 (33%) | 15 (68%) |
| 3: Medium | 2 (67%) | 3 (14%) |
| 4: Heavy | 0 (0%) | 1 (4%) |
| Physical activity score, job and leisure, n (%) | n total DK = 63 | n total Pa = 48 |
| 1: Sedentary | 5 (8%) | 10 (21%) |
| 2: Light | 31 (49%) | 28 (58%) |
| 3: Medium | 22 (35%) | 9 (19%) |
| 4: Heavy | 5 (8%) | 1 (2%) |
| Self-rated health, n (%) | n total DK = 66 | n total Pa = 70 |
| 1: Very good | 24 (36%) | 5 (7%) |
| 2: Somewhat good | 37 (56%) | 34 (49%) |
| 3: Somewhat bad | 4 (6%) | 23 (33%) |
| 4: Very bad | 1 (2%) | 8 (11%) |
| Self-rated health compared to others of same age, n (%) | n total DK = 66 | n total Pa = 70 |
| 1: A lot better | 6 (9%) | 4 (6%) |
| 2: Somewhat better | 16 (24%) | 21 (30%) |
| 3: The same | 40 (61%) | 27 (38%) |
| 4: Worse | 4 (6%) | 18 (26%) |
1Participant divided according to job situation in order to determine physical activity during their daily activities. Participant with a job were asked about activity during work and leisure time, participants without a job were asked about activities throughout the day, the only difference were the formulation of the questions. Physical activity score is a mean of eight self-rated questions on physical activity and sedentary time. The questions on physical activity is adapted from a previous intervention study [33]
Markers of bone turnover: OC, CTX, BALP, P1NP at baseline, endpoint and the change following intervention1
| Danish | Pakistani | ||||
|---|---|---|---|---|---|
| Placebo ( | Fortified ( | Placebo ( | Fortified ( | ||
| OC (μg/L) | |||||
| Baseline | 23.9 (9.6)d | 25.2 (8.7)bc | 19.6 (8.4)c | 18.2 (5.6)bd | 0.001 |
| Endpoint | 22.3 (9.0) | 22.7 (6.8)b | 19.5 (8.9) | 17.4 (5.0)b | 0.03 |
| Change | −1.2 (4.2) | −2.3 (4.6) | −0.20 (4.0) | −0.5 (2.9) | 0.19 |
| CTX (ng/mL) | |||||
| Baseline | 0.25 (0.14) | 0.30 (0.15) | 0.27 (0.19) | 0.21 (0.1) | 0.13 |
| Endpoint | 0.23 (0.14) | 0.26 (0.12) | 0.24 (0.16) | 0.19 (0.1) | 0.20 |
| Change | −0.006 (0.1) | − 0.05 (0.1) | − 0.03 (0.1) | − 0.02 (0.1) | 0.38 |
| BALP (μg/L) | |||||
| Baseline | 15.5 (7.0) | 16.6 (5.2) | 15.9 (5.2) | 16.9 (7.9) | 0.79 |
| Endpoint | 13.4 (5.4) | 14.0 (4.4) | 14.6 (4.9) | 14.6 (6.0) | 0.74 |
| Change | −1.5 (3.5) | −1.5 (3.6) | − 1.4 (2.1) | − 1.8 (4.5) | 0.97 |
| P1NP (μg/L) | |||||
| Baseline | 50.7 (25.2) | 54.6 (19.6) | 46.6 (19.6) | 48.1 (17.2) | 0.42 |
| Endpoint | 46.4 (23.8) | 51.1 (16.8) | 48.5 (21.0) | 45.7 (14.7) | 0.72 |
| Change | −2.0 (7.9) | −2.6 (11.0) | 1.7 (10.3) | −1.7 (10.4) | 0.31 |
1Means and SD unless otherwise specified.
2P values for comparisons over the four study groups were determined with the use of a one-way ANOVA followed by Tukey’s HSD test. Significant comparisons a: DK Placebo vs DK Fortified, b: PA Fortified vs DK Fortified, c: PA Placebo vs DK Fortified, d: PA Fortified vs DK Placebo, e: PA Placebo vs DK Placebo, f: PA Placebo vs PA Fortified.
OC Osteocalcin, BALP Bone specific Alkaline Phosphatase, P1NP Procollagen type 1 amino-terminal propeptide, CTX C-terminal crosslinked telopeptide of type 1 collagen
Muscle strength and body composition at baseline, endpoint and the change following intervention
| Danish | Pakistani | ||||
|---|---|---|---|---|---|
| Placebo ( | Fortified ( | Placebo ( | Fortified ( | ||
| Handgrip strength (kg) | |||||
| Baseline | 34.5 (4.2)de | 33.2 (4.2)c | 27.9 (6.6)ce | 30.3 (6.2)d | < 0.001 |
| Endpoint | 34.07 (3.8)de | 33.3 (4.3)c | 28.0 (6.1)ce | 30.3 (5.5)d | < 0.001 |
| Change | −0.46 (2.3) | − 0.1 (3.0) | 0.2 (3.0) | 0.5 (3.5) | 0.66 |
| Knee extension strength (kg) | |||||
| Baseline | 34.0 (5.7)e | 36.5 (5.9)bc | 27.7 (6.5)ce | 31.1 (7.7)b | < 0.001 |
| Endpoint | 35.0 (5.9)e | 37.5 (5.4)bc | 27.5 (6.7)ce | 31.2 (7.8)b | < 0.001 |
| Change | 0.3 (4.5) | 1.0 (3.9) | −0.15 (5.0) | 0.6 (4.3) | 0.79 |
| Chair-stand test (Mean rep/min) | |||||
| Baseline | 23.4 (5.9) | 24.0 (5.0)c | 19.9 (5.5)c | 22.6 (7.1) | 0.04 |
| Endpoint | 24.7 (6.6) | 26.8 (6.5)c | 21.9 (5.9)c | 23.9 (7.2) | 0.045 |
| Change | 1.2 (3.0) | 2.7 (3.6) | 1.3 (3.4) | 1.6 (3.6) | 0.35 |
| Mean BMI (kg/m2) | |||||
| Baseline | 24.6 (5.1) | 24.1 (4.0)bc | 27.1 (24.8)c | 27.4 (4.7)b | 0.007 |
| Endpoint | 24.4 (4.3) | 24.1 (3.9)bc | 27.2 (5.1)c | 27.2 (4.3)b | 0.005 |
| Change | 0.1 (0.5) | 0.2 (0.5) | 0.2 (0.5) | 0.1 (0.5) | 0.97 |
| Mean fat % | |||||
| Baseline | 32.6 (7.6)de | 30.1 (7.3)bc | 37.1 (6.1)ce | 37.6 (5.7)bd | < 0.001 |
| Endpoint | 32.0 (7.4)de | 30.7 (7.1)bc | 36.6 (6.4)ce | 37.4 (5.6)bd | < 0.001 |
| Change | −0.11 (1.9) | 0.7 (2.3) | −0.3 (1.4) | 0.16 (1.7) | 0.20 |
| Mean lean mass (kg) | |||||
| Baseline | 46.5 (4.7)e | 47.1 (3.0)bc | 42.8 (4.7)ce | 43.8 (4.7)b | < 0.001 |
| Endpoint | 46.5 (4.3)de | 46.8 (3.0)bc | 43.2 (4.8)ce | 43.16 (4.1)bd | < 0.001 |
| Change | 0.22 (1.3) | −0.05 (1.3) | 0.43 (1.0) | 0.06 (0.87) | 0.37 |
1Means and SD unless otherwise specified.
2P values for comparisons over the four study group were determined with the use of a one-way ANOVA followed by Tukey’s test. Significant comparisons a: DK Placebo vs DK Fortified, b: PA Fortified vs DK Fortified, c: PA Placebo vs DK Fortified, d: PA Fortified vs DK Placebo, e: PA Placebo vs DK Placebo, f: PA Placebo vs PA Fortified.
The effect of intervention with vitamin D fortified foods on the markers of bone turnover OC, BALP, P1NP and CTX, analysed in an ANCOVA including the baseline covariates that may influence the outcome (age, ethnicity, intervention group and BMI)
| Coefficients | Estimate | 95% CI | Estimate | 95% CI | ||
|---|---|---|---|---|---|---|
| Δ OC | Model 1 (minimal) | Model 2 (maximal) | ||||
| Intercept1 | 3.14 | (0.95; 5.32) | 0.005 (**) | 6.53 | (1.69; 11.4) | 0.01 (*) |
| Baseline OC | −0.20 | (− 0.27; − 0.12) | < 0.0001 (***) | − 0.21 | (− 0.29; − 0.13) | < 0.0001 (***) |
| Ethnicity: | ||||||
| Danish | – | – | – | – | – | – |
| Pakistani | 0.50 | (−0.87; 1.83) | 0.50 | −0.70 | (− 0.67; 2.07) | 0.31 |
| Intervention group: | ||||||
| Fortified | −0.57 | (−1.87; 0.72) | 0.39 | −0.60 | (−1.86; 0.66) | 0.35 |
| Placebo | – | – | – | – | – | – |
| BMI | −0.10 | (− 0.25; 0.05) | 0.20 | |||
| Age | − 0.01 | (−0.08; 0.06) | 0.69 | |||
| Δ BALP | Model 1 (minimal) | Model 2 (maximal) | ||||
| Intercept1 | 3.4 | (1.93; 4.94) | < 0.0001 (***) | 0.50 | (−2.6; 3.59) | 0.75 |
| Baseline BALP | −0.32 | (−0.40; − 0.24) | < 0.0001 (***) | −0.25 | (− 0.33; − 0.17) | < 0.0001 (***) |
| Ethnicity: | ||||||
| Danish | – | – | – | – | – | – |
| Pakistani | 0.2 | (−0.84; 1.23) | 0.71 | 0.07 | (− 0.93; 1.08) | 0.88 |
| Intervention group: | ||||||
| Fortified | −0.03 | (−1.06; 1.00) | 0.95 | 0.19 | (−0.76; 1.13) | 0.70 |
| Placebo | – | – | – | – | – | – |
| BMI | 0.05 | (−0.07; 0.16) | 0.43 | |||
| Age | 0.02 | (−0.03; 0.07) | 0.42 | |||
| Δ P1NP | Model 1 (minimal) | Model 2 (maximal) | ||||
| Intercept1 | 6.81 | (1.78; 11.84) | 0.005 (**) | 13.4 | (1.10; 25.8) | 0.03 (*) |
| Baseline P1NP | −0.17 | (− 0.25; − 0.09) | < 0.0001 (***) | − 0.19 | (− 0.28; − 0.11) | < 0.0001 (***) |
| Ethnicity: | ||||||
| Danish | – | – | – | – | – | – |
| Pakistani | 1.88 | (−1.52; 5.28) | 0.28 | 1.79 | (−1.78; 5.35) | 0.32 |
| Intervention group: | ||||||
| Fortified | −1.36 | (−4.75; 2.04) | 0.43 | −1.63 | (−5.02; 1.76) | 0.34 |
| Placebo | – | – | – | – | – | – |
| BMI | 0.04 | (−0.37; 0.45) | 0.85 | |||
| Age | −0.18 | (−0.36; 0.01) | 0.07 | |||
| Δ CTX | Model 1 (minimal) | Model 2 (maximal) | ||||
| Intercept1 | 0.06 | (0.03; 0.10) | < 0.0001 (***) | 7.2−2 | (−0.03; 0.17) | 0.15 |
| Baseline CTX | −0.33 | (−0.42; − 0.23) | < 0.0001 (***) | −0.33 | (− 0.43; − 0.23) | < 0.0001 (***) |
| Ethnicity: | ||||||
| Danish | – | – | – | – | – | – |
| Pakistani | −0.004 | (−0.03; 0.02) | 0.80 | −0.003 | (− 0.03; 0.03) | 0.82 |
| Intervention group: | ||||||
| Fortified | −0.01 | (−0.04; 0.02) | 0.40 | −0.01 | (− 0.04; 0.01) | 0.37 |
| Placebo | – | – | – | – | – | – |
| BMI | −2.1−4 | (−0.004; 0.003) | 0.91 | |||
| Age | −2.8−6 | (−0.002; 0.002) | 1.00 | |||
1The reference group is included in the intercept: Danish ethnicity and placebo study group
The change in muscle strength measured as handgrip strength and knee extension strength and a 30 s chair-standing test, analysed in an ANCOVA including the baseline covariates that may influence the outcome (age, ethnicity, intervention group and BMI)
| Coefficients | Estimate | 95% CI | Estimate | 95% CI | ||
|---|---|---|---|---|---|---|
| Δ Handgrip strength | Model 1 (minimal) | Model 2 (maximal) | ||||
| Intercept1 | 6.80 | (3.56; 10.0) | < 0.0001 (***) | 6.56 | (2.32; 10.8) | < 0.003 (**) |
| Baseline handgrip strength | −0.21 | (−0.31; − 0.12) | < 0.0001 (***) | − 0.22 | (− 0.31; − 0.12) | < 0.0001 (***) |
| Ethnicity: | ||||||
| Danish | – | – | – | – | – | – |
| Pakistani | − 0.53 | (−1.63; 0.58) | 0.35 | − 0.63 | (−1.82; 0.56) | 0.30 |
| Intervention group: | ||||||
| Fortified | 0.38 | (−0.62; 1.37) | 0.46 | 0.48 | (−0.54; 1.50) | 0.35 |
| Placebo | – | – | – | – | – | – |
| BMI | 0.01 | (−0.11; 0.13) | 0.88 | |||
| Age | −0.003 | (−0.05; 0.06) | 0.99 | |||
| Δ Knee extension strength | Model 1 (minimal) | Model 2 (maximal) | ||||
| Intercept1 | 8.66 | (4.16; 13.16) | < 0.0001 (***) | 9.93 | (3.82; 16.21) | < 0.0001 (***) |
| Baseline knee extension strength | −0.24 | (−0.37; − 0.12) | < 0.0001 (***) | − 0.25 | (− 0.38; − 0.12) | < 0.0001 (***) |
| Ethnicity: | ||||||
| Danish | – | – | – | – | – | – |
| Pakistani | −1.96 | (−3.69; − 0.23) | 0.03 (*) | −1.95 | (−4.24; 0.54) | 0.03 (*) |
| Intervention group: | ||||||
| Fortified | 1.23 | (−0.34; 2.81) | 0.12 | 1.21 | (−0.94; 3.52) | 0.13 |
| Placebo | – | – | – | – | – | – |
| BMI | −0.02 | (−0.20; 0.18) | 0.87 | |||
| Age | −0.03 | (−0.11; 0.06) | 0.46 | |||
| Δ Chair-standing test | Model 1 (minimal) | Model 2 (maximal) | ||||
| Intercept1 | 2.54 | (−0.22; 5.31) | 0.07 | 5.90 | (0.78; 11.0) | 0.02 (*) |
| Baseline chair-standing | −0.05 | (− 0.15; 0.06) | 0.41 | − 0.06 | (− 0.17; 0.06) | 0.30 |
| Ethnicity: | ||||||
| Danish | – | – | – | – | – | – |
| Pakistani | −0.56 | (−1.86; 0.74) | 0.39 | −0.01 | (−1.45; 1.24) | 0.88 |
| Intervention group: | ||||||
| Fortified | 0.94 | (−0.34; 2.22) | 0.15 | 0.93 | (−0.34; 2.20) | 0.15 |
| Placebo | – | – | – | – | – | – |
| BMI | −0.16 | (−0.31; − 0.004) | 0.04 (*) | |||
| Age | 0.02 | (−0.05; 0.09) | 0.56 | |||
1The reference group is included in the intercept: Danish ethnicity and placebo study group